NASD · Healthcare · Biotechnology · USA
Innoviva Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Innoviva is a biopharmaceutical company with a royalty portfolio of respiratory products partnered with GSK, including RELVAR/BREO ELLIPTA and ANORO ELLIPTA. The company operates Innoviva Specialty Therapeutics, a critical care and infectious disease platform with five approved commercial products: GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE. Innoviva also holds strategic healthcare investments, including a stake in Armata Pharmaceuticals.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Innoviva Inc stock.
Undervalued: intrinsic value $73.58 per share, market price $21.28, margin of safety 71.1% (as of 2026-10-20).
Discounting its cash flows at 7.5% (average of 3 methods) values the shares at $73.58; the price of $21.28 is 71% below that value, and 82% of that value comes from beyond year five.
Leak Score: 73/100 on 12 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
INVA is undervalued (as of the 2026-10-20 close). Discounting its cash flows at 7.5% (average of 3 methods) values the shares at $73.58; the price of $21.28 is 71% below that value, and 82% of that value comes from beyond year five.
$73.58 per share (as of the 2026-10-20 close), against a market price of $21.28. That is a margin of safety of 71.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
73 out of 100, which we rate "Clear Leak", on 12 of 12 value investing signals.